2-Hydroxyoleic Acid for Autoimmune B Cell Apoptosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases such as systemic lupus erythematosus (SLE) are limited in effectiveness, and there is a need to improve B cell tolerance mechanisms to reduce self-reactive B cells and autoantibodies, which contribute to autoimmune pathology.
Innovation Solution
Administering 2-hydroxyoleic acid (2OHOA) to stimulate sphingomyelin synthase 2 (SMS2) activity, promoting PKCδ-mediated apoptosis of self-reactive B cells and enhancing B cell tolerance, potentially in combination with other immunomodulatory compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for autoimmune diseases, then some therapeutic effect is achieved, but effectiveness is limited and B cell tolerance mechanisms are not sufficiently improved
Solution Approach 1:
The patent changes the biochemical parameters within B cells by administering 2-hydroxyoleic acid, which alters sphingomyelin metabolism and activates PKCδ signaling pathway. This parameter change in cellular biochemistry leads to enhanced apoptosis of self-reactive B cells and improved B cell tolerance, thereby resolving the contradiction between treatment effectiveness and B cell tolerance enhancement
Solution Approach 2:
The patent introduces 2-hydroxyoleic acid as an intermediary substance that mediates between the administered treatment and the B cell tolerance mechanisms. This intermediary activates SMS2 enzyme and PKCδ signaling, serving as a bridge to achieve selective apoptosis of self-reactive B cells while sparing normal B cells, thus improving both treatment effectiveness and B cell tolerance
2Object-generated harmful factors
If self-reactive B cells are eliminated to reduce autoantibodies, then autoimmune pathology is reduced, but B cell diversity and immune response capability may be compromised
Solution Approach 1:
The patent selectively extracts or removes only the harmful self-reactive B cells from the B cell population through enhanced apoptosis mediated by PKCδ activation. By targeting specifically the pathogenic subset rather than eliminating all B cells, the treatment reduces autoantibody levels while preserving the diverse repertoire of normal B cells needed for immune response
Solution Approach 2:
The patent employs a feedback mechanism where 2-hydroxyoleic acid activates PKCδ in B cells that exhibit specific characteristics of self-reactivity. The activated PKCδ creates a feedback loop that promotes apoptosis specifically in cells with abnormal activation patterns, thereby eliminating autoantibody-producing cells while maintaining normal B cell function and diversity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
2OHOA treatment reduces the levels of autoantibodies and ameliorates autoimmune disorder symptoms by promoting the apoptosis of self-reactive B cells, thereby improving B cell tolerance and reducing autoimmune pathology.
Implementation Method 1
promoting PKCδ-mediated apoptosis of self-reactive B cells
Data Source
AI summary
Provided is a method of reducing autoimmunity, including reducing an amount of self-reactive B cells in a subject expressing elevated levels of an autoantibody, wherein reducing includes administering 2-hydroxyoleic acid to the subject. Also provided is a method of treatment including administering 2-hydroxyoleic acid to a subject expressing elevated levels of an auto-antibody. Also provided is a method of promoting B cell tolerance, including promoting apoptosis of self-reactive B cells in a subject, wherein promoting includes administering 2-hydroxyoleic acid to the subject.